收费全文 | 5296篇 |
免费 | 290篇 |
国内免费 | 84篇 |
耳鼻咽喉 | 118篇 |
儿科学 | 156篇 |
妇产科学 | 90篇 |
基础医学 | 546篇 |
口腔科学 | 92篇 |
临床医学 | 673篇 |
内科学 | 1040篇 |
皮肤病学 | 21篇 |
神经病学 | 110篇 |
特种医学 | 402篇 |
外科学 | 1230篇 |
综合类 | 514篇 |
预防医学 | 113篇 |
眼科学 | 50篇 |
药学 | 253篇 |
1篇 | |
中国医学 | 47篇 |
肿瘤学 | 214篇 |
2024年 | 14篇 |
2023年 | 119篇 |
2022年 | 200篇 |
2021年 | 221篇 |
2020年 | 191篇 |
2019年 | 182篇 |
2018年 | 202篇 |
2017年 | 155篇 |
2016年 | 145篇 |
2015年 | 151篇 |
2014年 | 303篇 |
2013年 | 315篇 |
2012年 | 225篇 |
2011年 | 280篇 |
2010年 | 211篇 |
2009年 | 246篇 |
2008年 | 249篇 |
2007年 | 249篇 |
2006年 | 228篇 |
2005年 | 196篇 |
2004年 | 172篇 |
2003年 | 145篇 |
2002年 | 107篇 |
2001年 | 106篇 |
2000年 | 80篇 |
1999年 | 109篇 |
1998年 | 87篇 |
1997年 | 86篇 |
1996年 | 72篇 |
1995年 | 65篇 |
1994年 | 68篇 |
1993年 | 55篇 |
1992年 | 57篇 |
1991年 | 42篇 |
1990年 | 29篇 |
1989年 | 39篇 |
1988年 | 30篇 |
1987年 | 24篇 |
1986年 | 27篇 |
1985年 | 30篇 |
1984年 | 30篇 |
1983年 | 14篇 |
1982年 | 22篇 |
1981年 | 22篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 6篇 |
1973年 | 3篇 |
Purpose
Chest wall pain is an uncommon but bothersome late complication following lung stereotactic body radiation therapy. Despite numerous studies investigating predictors of chest wall pain, no clear consensus has been established for a chest wall constraint. The aim of our study was to investigate factors related to chest wall pain in a homogeneous group of patients treated at our institution.Patients and methods
All 122 patients were treated with the same stereotactic body radiation therapy regimen of 48 Gy in three fractions, seen for at least 6 months of follow-up, and planned with heterogeneity correction. Chest wall pain was scored according to the Common Terminology Criteria for Adverse Events classification v3.0. Patient (age, sex, diabetes, osteoporosis), tumour (planning target volume, volume of the overlapping region between planning target volume and chest wall) and chest wall dosimetric parameters (volumes receiving at least 30, 40, and 50 Gy, the minimal doses received by the highest irradiated 1, 2, and 5 cm3, and maximum dose) were collected. The correlation between chest wall pain (grade 2 or higher) and the different parameters was evaluated using univariate and multivariate logistic regression.Results
Median follow-up was 18 months (range: 6–56 months). Twelve patients out of 122 developed chest wall pain of any grade (seven with grade 1, three with grade 2 and two with grade 3 pain). In univariate analysis, only the volume receiving 30 Gy or more (P = 0.034) and the volume of the overlapping region between the planning target volume and chest wall (P = 0.038) significantly predicted chest wall pain, but these variables were later proved non-significant in multivariate regression.Conclusion
Our analysis could not find any correlation between the studied parameters and chest wall pain. Considering our present study and the wide range of differing results from the literature, a reasonable conclusion is that a constraint for chest wall pain is yet to be defined. 相似文献Methods: All women who were diagnosed with cutaneous endometriosis and underwent HIFU ablation and 4-year follow-up were included. Patient symptoms, imaging performed, HIFU ablation, recurrence, lesion location, size and number were collected and analyzed.
Results: A total of 51 women with 57 painful abdominal wall masses with a median volume of 4.00?cm3 and a mean age of 30.5±2.12 years were treated with HIFU. The main symptoms were a palpable painful abdominal mass (93%), protrusion of the skin (28.1%, 16) or lack of protrusion of the skin (71.9%, 41). Ultrasound was initially performed in 100% (51) of women, whereas 6% (3) required MRI examinations to distinguish the features and range of the masses. Ablation was performed with a median 300?s of sonication time, 40?min treatment time, 150?W of power and 41800?J of total energy to treat lesions that were a median volume of 3.83?cm3. No severe complications occurred, except in one patient with a first-degree skin burn, during the 48-month follow-up period. The pooled recurrence of cutaneous endometriosis occurred in 3.9% (2) of women.
Conclusion: The diagnosis of AWE should be confirmed with imaging of the lesion number, location, size and features before HIFU ablation. HIFU should be the first choice for the treatment of AWE as it is a non-invasive method, with high efficiency and safety and rapid postoperative recovery. 相似文献